Highlights
- AVITA Medical (ASX:AVH) reported USD 26.1 million in third-quarter revenue.
- Q3 Revenue increased 53% year on year and 20% sequentially.
- The company raised 2026 revenue guidance to USD 92–94 million.
- Cash and marketable securities stood at approximately USD 10.5 million.
AVITA Medical, Inc. (ASX:AVH) develops and commercialises technologies for treating acute wounds, including its RECELL system and complementary wound-care products. On 13 November 2026, its ASX-listed securities were trading at AUD 4.78, down 5.53% during the session. The company’s November financial release reported higher third-quarter revenue, a narrower net loss and updated full-year guidance, alongside changes relevant to US reimbursement for RECELL procedures.
RECELL and Complementary Wound-Care Products
AVITA’s RECELL platform prepares a suspension of a patient’s own skin cells for use in treating specified burn and trauma wounds. The company also markets Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its Business combines product sales, clinical adoption, Manufacturing and hospital purchasing processes, principally within the United States.
Commercial performance depends on the number of relevant procedures, hospital adoption and access to reimbursement. The company also distributes products across certain international markets. The scope of each product’s authorisations and its clinical indications differs, so sales progress should not be read as evidence of broader regulatory approval.
Third-Quarter 2026 Revenue and Product Mix
For the three months ended 30 September 2026, AVITA Medical (ASX:AVH) reported total revenue of USD 26.1 million, increasing 53% from USD 17.1 million a year earlier and 20% from the preceding quarter. Revenue from RECELL in the United States was USD 22.4 million, approximately 20% higher than in the June quarter.
Cohealyx contributed USD 2.1 million of revenue, approximately 21% above the preceding quarter. PermeaDerm recorded USD 0.6 million, while international revenue was approximately USD 0.9 million. The company reported an 84.0% gross margin, up 270 basis points from the comparable quarter, citing product mix and manufacturing efficiency.
Losses, Liquidity and Guidance
AVITA reported a quarterly net loss of USD 6.2 million, compared with a loss of USD 13.2 million in the prior-year quarter. Operating expenses were USD 24.6 million, broadly unchanged sequentially. Net cash use was approximately USD 0.6 million, compared with USD 3.2 million in the second quarter.
Cash, cash equivalents and marketable securities totalled approximately USD 10.5 million at 30 September 2026. After quarter-end, the company drew an additional USD 10 million under an existing Credit facility, following achievement of a trailing twelve-month revenue milestone of USD 85 million. The additional borrowing improves immediate liquidity but also increases obligations under the facility.
AVITA Medical (ASX:AVH) increased its full-year 2026 revenue guidance to USD 92 million–USD 94 million from the earlier USD 86 million–USD 89 million range. Management reiterated its expectation of reaching cash-flow breakeven in the fourth quarter. This is management guidance, not an achieved outcome.
Reimbursement Changes and Clinical Updates
In November 2026, AVITA reported that the US Centers for Medicare & Medicaid Services finalised national physician payment values and simplified billing codes for RECELL procedures, effective from January 2027. Payment rules can affect the administrative and economic setting in which hospitals and clinicians use medical technologies.
The company also highlighted results from its PermeaDerm I study, reporting comparable clinical outcomes to allograft together with 70% lower product cost and 95.7% less preparation time in the specified study comparison. Such findings refer to the studied setting and should not be extended to every clinical use.
Risks and What to Watch Next
Relevant risks include reimbursement implementation, product adoption, manufacturing execution, clinical evidence, Debt obligations and cash requirements. Gross Margin and quarterly cash use may vary with sales mix and operating expenditure. Investors may monitor the December-quarter result, whether management’s cash-flow objective is achieved and how the revised reimbursement framework is implemented.
Key Insights
AVITA’s third-quarter report documented growth across its wound-care portfolio, a smaller net loss and updated revenue guidance. The business nevertheless remained loss-making during the reported quarter. RECELL volumes, reimbursement arrangements, Operating Cash Flow and funding requirements remain the principal disclosed monitoring points.
_11_16_2026_07_52_44_870464.jpg)





Please wait processing your request...